Interaction between CRHR1 and BDNF Genes Increases the Risk of Recurrent Major Depressive Disorder in Chinese Population

Zheman Xiao1,3, Wanhong Liu1,3, Kai Gao3, Qirong Wan3, Can Yang3, Huiling Wang3, Xiaoping Wang3, Gaohua Wang1,3, Zhongchun Liu1,3*

1 Institute of Neuropsychiatry, Wuhan University, Wuhan, China, 2 School of Medicine, Wuhan University, Wuhan, China, 3 Department of Psychiatry, Renmin Hospital, Wuhan University, Wuhan, China

Abstract

Background: An important etiological hypothesis about depression is stress has neurotoxic effects that damage the hippocampal cells. Corticotropin-releasing hormone (CRH) regulates brain-derived neurotrophic factor (BDNF) expression through influencing cAMP and Ca2+ signaling pathways during the course. The aim of this study is to examine the single and combined effects of CRH receptor 1 (CRHR1) and BDNF genes in recurrent major depressive disorder (MDD).

Methodology/Principal Finding: The sample consists of 181 patients with recurrent MDD and 186 healthy controls. Whether genetic variations interaction between CRHR1 and BDNF genes might be associated with increased susceptibility to recurrent MDD was studied by using a gene-based association analysis of single-nucleotide polymorphisms (SNPs). CRHR1 gene (rs1876828, rs242939 and rs242941) and BDNF gene (rs6265) were identified in the samples of patients diagnosed with recurrent MDD and matched controls. Allelic association between CRHR1 rs242939 and recurrent MDD was found in our sample (allelic: p = 0.018, genotypic: p = 0.022) with an Odds Ratio 0.454 (95% CI 0.266–0.775). A global test of these four haplotypes showed a significant difference between recurrent MDD group and control group (chi-2 = 13.117, df = 3, P = 0.016. Furthermore, BDNF and CRHR1 interactions were found in the significant 2-locus, gene–gene interaction models (p = 0.05) using a generalized multifactor dimensionality reduction (GMDR) method.

Conclusion: Our results suggest that an interaction between CRHR1 and BDNF genes constitutes susceptibility to recurrent MDD.

Introduction

Major depressive disorder (MDD) is frequently characterized by periodic depressed mood and the loss of interest, often with thoughts of death. Severe forms of depression affect 2–5% of the population worldwide, and up to 20% suffer from milder forms of the disease, and depression is also associated with high rates of relapse, recurrent, disability, and death [1]. Despite the high morbidity and mortality associated with MDD, the etiology and pathophysiology of MDD have not been precisely defined. Family, twin, and adoption studies provide strong evidence for an important genetic component [2]. To uncover the genetic mechanisms underlying susceptibility to depression and related traits may also prove a successful way to understand better the etiological features of MDD [3].

Stress response and neurotoxic effects are important etiological hypotheses about depression. Neurotoxins (possibly related to excessive corticotrophin activity and/or to the inflammatory effects of cytokines) damage or kill hippocampal cells, leading to many depressive symptoms. A deficient function of neuroprotective peptides, for example, brain-derived neurotrophic factor (BDNF), which reduces serum BDNF in MDD [4]. Hypothalamic-pituitary-adrenal (HPA) axis dysregulation and reduced neuroplasticity in depression are consistent with the assumption that BDNF is a stress-responsive intercellular messenger modifying HPA axis activity [5]. As a major mediator of the stress response in the central nervous system, corticotropin releasing hormone (CRH) affects other central processes, such as learning and memory, synaptic plasticity, and neuroprotection [6]. Abnormal CRH neurotransmission and receptor signal transduction has been proposed to be a critical mechanism for stress pathophysiology that leads to major depression [7]. Bayatti et al considered that CRH regulates BDNF expression through influencing cAMP and Ca2+ signaling pathways [8].

Citation: Xiao Z, Liu W, Gao K, Wan Q, Yang C, et al. (2011) Interaction between CRHR1 and BDNF Genes Increases the Risk of Recurrent Major Depressive Disorder in Chinese Population. PLoS ONE 6(12): e28733. doi:10.1371/journal.pone.0028733

Copyright: © 2011 Xiao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the National Natural Science Foundation of China (30971040), National Key Technology R&D Program during the 11th Five-Year of China (2007BAI17B05), Nature Science Foundation of Hubei Province (2005ABA105), Youth Talent Foundation of Hubei Province Hygiene Department (QJX2008-23), the 985 Project of Cognitive and Neural Information Science, Wuhan University, P. R. China within the promotional emphasis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

These authors contributed equally to this work.
Based on different neuroanatomical expression patterns, there are two primary receptors subtypes in the central nervous system CRHR1 and CRHR2 [9]. CRH has a higher affinity for CRHR1 than for CRHR2, and in the brain, CRHR1 is expressed at high levels in the hippocampus, cortex and cerebellum [10]. CRH binding to CRHR1 typically activates adenylyl cyclase (AC), which leads to increased intracellular concentrations of cAMP and activation of protein kinase A. One putative target is the BDNF, whose expression is controlled by cAMP-elevating agents in neurons [11]. In addition to its role as a classical target-derived growth factor during neuronal development, BDNF is an essential autocrine factor, released and acting locally after neuronal depolarization [12].

As CRHR1 may play a significant role in the etiology and treatment of depression, it is suggested that CRHR1 is a relevant candidate gene for MDD. In Mexican-Americans population, a significant association has been reported between CRHR1 and a greater response to selective serotonin reuptake inhibitors (SSRI) treatment in highly anxious MDD patients [13], but the distribution of the MDD was similar to the healthy controls. We have already reported that rs242939 AG carriers of CRHR1 have a greater risk of MDD in Han Chinese population, which showed marked geographical and ethnic variability of MDD [14], and that CRHR1 gene is likely to be involved in the antidepressant response in MDD [15]. Ressler et al reported a gene by gene-by-environment (G×G×E) interaction between the CRHR1, the 5-HTTLPR polymorphisms, and childhood abuse on depressive symptoms [16].

The BDNF gene rs6265 (G196A) polymorphism is functionally relevant [17]. The expression of BDNF is modified by antidepressant treatment [18]. Most association studies of BDNF polymorphism and depression related traits have yielded negative results. However, several lines of evidence suggest that lower active BDNF (rs6265) polymorphism is associated with the features associated with the risk of depression [19].

Addressing gene-gene interactions is crucial to characterizing a trait involving complex disease-related mechanisms, particularly when each feature only demonstrates a minor marginal effect [20]. Gene-gene interactions have been hypothesized to contribute to the etiology of depression [21]. Considering the higher heritability of recurrent depression than single episode depression, analyzing these two groups separately was much more important [22]. On the basis of a large number of studies, we undertook a case-control study to examine the combined effects of CRHR1 and BDNF genes on recurrent MDD in Chinese Han people.

### Results

In our total sample size (n = 367), power analysis for case-control samples was carried out by G* Power program, the sample size had a post-hoc power of 0.99 to detect an effect size of 0.5 (moderate) at the 0.05 significance level (2-tailed). Genotype distributions for the four SNPs were in Hardy–Weinberg equilibrium. The results from single marker analysis of these four SNPs are presented in Table 1. An allelic association between CRHR1 rs242939 and recurrent MDD was found in our sample (allelic: p = 0.018, genotypic: p = 0.022) with an Odds Ratio of 0.454 (95% CI 0.266–0.775), which is reflected by a significant increase of the G-allele of 242939 in the recurrent MDD group than the control group. CRHR1 (rs1876828, rs242941) and BDNF (rs6265) alleles were found no association with the risk of recurrent MDD in present sample (p = 0.1952, 0.0822, 0.4078 respectively).

Haplotype frequencies in the MDD group and in the control group were estimated using the EM algorithm embedded. Four common haplotypes (G-A-G, G-A-T, A-A-T, G-G-T respectively) of the SNPs of rs1876828, rs242939, rs242941, were found to present in the sample. Using chi-2 test, a global test of these four haplotypes showed a significant different distribution between the recurrent MDD group and the control group (chi-2 = 13.104, df = 3, P = 0.016) (Table 2).

To assess further combined effects of these genetic variants on recurrent MDD risk by using GMDR analysis. The GMDR software provides a number of output parameters, including CV consistency, the testing balanced accuracy, and empirical p values, to assess each selected interaction. The CV consistency score is a measure of the degree of consistency with which the selected interaction is identified as the best model among all possibilities considered. Furthermore, the testing balanced accuracy is a measure of the degree to which the interaction accurately predicts case–control status with scores between 0.50 (indicating that the model predicts no better than chance) and 1.00 (indicating perfect

### Table 1. Allele and genotype distribution of CRHR1 and BDNF polymorphisms of recurrent MDD patients and controls.

| Gene   | SNP ID* | Position | Genotype | p   | Allele | p   | Odds Ratio (95%CI) |
|--------|---------|----------|----------|-----|--------|-----|------------------|
|        |         |          | AA       | AG  | GG     | A   | G                |
| BDNF   | rs6265  | chr11:27679916 MDD | 39 | 87 | 55 | 0.4301 | 165 | 197 | 0.4078 | 1.134 |
|        |         | CON      | 37 | 84 | 65 | 0.0822 | 158 | 214 | 0.847 | 1.519 |
| CRHR1  | rs1876828 | chr17:43911525 MDD | 149 | 30 | 2 | 0.018 | 328 | 34 | 0.1952 | 1.395 |
|        |         | CON      | 143 | 39 | 4 | 0.022 | 325 | 47 | 0.874 | 2.226 |
|        | rs242939 | chr17:43895579 MDD | 139 | 40 | 2 | 0.018 | 318 | 44 | 0.266 | 0.775 |
|        |         | CON      | 166 | 18 | 2 | 0.0822 | 350 | 22 | 1.421 |
|        | rs242941 | chr17:43892520 MDD | 124 | 47 | 10 | 0.990 | 298 | 64 | 1.00  |

*SNP, single nucleotide polymorphism.

Bold numerals p-values after Bonferroni correction.

doi:10.1371/journal.pone.0028733.t001
The interaction between rs6265 of BDNF and rs242939 CRHR1 had a CV consistency of 10 and p value of 0.018 with recurrent MDD. This suggested that carrying this haplotype might increase the probability of developing recurrent MDD in Han Chinese population.

A large amount of literature has focused on studying the genetic association between the BDNF gene and MDD. However, genetic association studies of the BDNF rs6265 on MDD have produced inconsistent results. BDNF polymorphism is associated with increased risk of depression in some studies [23,24], while some studies found no association [25,26,27]. In the current study, using analysis of single loci, we did not find that BDNF rs6265 associated with recurrent MDD in Han Chinese population. There may be several interpretations for the discrepancy. Ethnic differences in polymorphism frequencies might contribute to inconsistent results in genetic association studies. Furthermore, MDD is a complex disease that is thought to be caused by multiple genetic factors in each small effect. Gene–gene interactions are likely to contribute to the pathophysiology of illness.

Using GMDR analyses, we further inferred the epistatic effects between CRHR1 and BDNF genes in recurrent MDD. We found a significant 2-locus (BDNF rs6265 and CRHR1 rs242939) gene–gene interaction models, which interactions confer an increased risk for recurrent MDD. Behavioral evidence supports that the CRHR1/BDNF system is involved in at least certain forms, such as learning and memory, synaptic plasticity [6]. The finding of CRHR1/BDNF interactions provides a better understanding of the genetic mechanisms of recurrent MDD.

Although evidence of a statistical interaction as we report here does not necessarily map directly onto a biological interaction, true gene–gene interactions nonetheless must have a biological basis [28]. Protein encoded by the CRHR1 and BDNF genes work together to result in lower BDNF in hippocampus. In depressed patients, a reduced volume of hippocampus has been reported, and this reduction in volume has been reversed by antidepressants [19]. There is also large number of studies suggesting a major role of BDNF in depression. BDNF rs6265 polymorphism is linked to substantial reduction in the volume of hippocampus, a brain structure repeatedly associated with the treatment response and neurogenesis in depression [29]. Our results further contribute to the hypothesized association between HPA axis dysregulation and reduced neuroplasticity in depression and are consistent with the assumption that BDNF is a stress-responsive intercellular messenger modifying HPA axis activity.

One limitation of this study is that the positive finding may be a result of type I error, but we addressed this limitation by using the Bonferroni correction. Second, our sample size is relatively small, however, our study had a power of 0.99 to detect an effect size of 0.5 (moderate) at the 0.05 significance level (2-tailed). Although the present study is preliminary, we suggested the interactional association of BDNF and CRHR1 in recurrent MDD should be replicated in large samples and in the other ethnic populations. Further work is required to investigate gene–gene interaction between other genes to progressively elucidate the pathophysiology involved in MDD.

**Table 2.** Haplotype analysis of recurrent MDD patients and controls.

| Haplotype | CON (%)<sup>a,b</sup> | MDD (%)<sup>a,b</sup> | chi-2 | df | P-value |
|-----------|--------------------------|--------------------------|--------|----|---------|
| GAG       | 0.66                     | 0.62                     | 1.063  | 1  | 0.151   |
| GAT       | 0.11                     | 0.11                     | 0.001  | 1  | 0.542   |
| AAG       | 0.13                     | 0.09                     | 2.423  | 1  | 0.06    |
| GGT       | 0.08                     | 0.16                     | 10.509 | 1  | 0.003<sup>c</sup> |
| Total     |                          |                          | 13.104 | 3  | 0.016<sup>c</sup> |

<sup>a</sup>Haplotype frequencies (%) estimation using the EM algorithm from Arlequin.
<sup>b</sup>All haplotypes estimated to occur with a frequency of at least 1% in MD patients or controls are represented.
<sup>c</sup>Bold numerals p-values after Bonferroni correction.

**Table 3.** Best gene–gene interactions models identified by the generalized multifactor dimensionality reduction (GMDR) method.

| Locus number | Best combination | Cross-validation consistency | Testing accuracy (%) | P-value |
|--------------|------------------|------------------------------|----------------------|---------|
| 2            | rs6265, rs242939 | 10/10                        | 59.16                | 0.05<sup>a</sup> |
| 4            | rs6265, rs242939, rs242941 | 10/10                      | 57.52                | 0.08<sup>a</sup> |

<sup>a</sup>Bold numerals p-values after Bonferroni correction.

doi:10.1371/journal.pone.0028733.t003
Materials and Methods

Subjects

The patient sample consisted of 181 unrelated Chinese MDD individuals (male/female: 72/109; mean age: 33.68±10.07 years), who were outpatients and inpatients from the Psychiatric Department of the Renmin Hospital of Wuhan University. All patients had at least two well-defined episodes of MDD (average number: 5.6) as defined by DSM-IV [30]. Patients were interviewed by trained psychiatrists using the Structured Clinical Interview for DSM-IV disorders (SCID-I). Severity of depression was assessed using the 21-item Hamilton Rating Scale for Depression (HAM-D-21) and the Clinical Global Impression Scale (CGI) [31,32]. Only subjects with a minimum score of 18 on the HAM-D-21 were selected. Patients with severe organic disorders or who showed comorbidity for other psychiatric disturbances (eg substance/alcohol dependence, personality disorders, anxiety disorders and others) were excluded. There were no significant differences concerning all other investigated variables (age, clinical variables such as CGI and HAM-D-21 scores) in males and females.

A total of 186 (male/female: 71/115; mean age: 32.94±11.32 years) healthy controls whose age, gender, and ethnically matched subjects were selected from the general population (Table 4). All patients and controls were Han people who came from the same geographical region in China. The Medical Ethics Committees of the Renmin Hospital of Wuhan University approved the research project. Patients were included in the study after they gave written informed consent.

Table 4. Population characteristics of recurrent MDD patients and controls.

|                      | Recurrent MDD | Controls |
|----------------------|---------------|----------|
| N                    | 181           | 186      |
| Age (mean±S.D.)      | 33.68±10.07   | 32.94±11.32 |
| Gender (males/females) | 72/109       | 71/115   |
| Age of onset(males/females) | 29.34±9.63   |          |
| Average onset times  | 3.6           |          |
| HAMD score           | 29.11±5.89    |          |


doi:10.1371/journal.pone.0028733.t004

Genotyping

Genomic DNA was extracted from EDTA-anticoagulated venous blood samples which were carried out as described by Miller et al [33]. In this study, four single-nucleotide polymorphisms (SNPs) were assayed corresponding to the following dbSNP identifiers: rs1876828, rs242939 and rs242941 (CRHR1 gene), rs6265 (BDNF gene). SNPs were genotyped with TaqMan technology (Assay-by-Design) on an ABI 7900 system (Applied Biosystems). All MGB TaqMan probes and PCR primers were designed by Applied Biosystems (Foster City, CA, USA). The standard PCR reaction was carried out using TaqManR Universal PCR Master Mix reagent kit in a 5 μl volume. Fluorescence data files from each plate were analyzed by using automated software ( SDS 2.1; Applied Biosystems). All laboratory procedures were carried out blind to case–control status.

Statistical analysis

The GENEPOP program was used to compare the overall allele and genotype distributions for each SNP in MDD patients and controls, and to test Hardy–Weinberg equilibrium [34]. Haplotypes frequencies in recurrent MD patients and controls were estimated using the EM algorithm embedded in the program Arlequin [35]. A total of 10,000 permutation tests were performed in each analysis. Bonferroni correction was used for multiple testing, using the total number of SNPs as correction factor. The GMDR analysis was used to assess gene–gene interactions [36]. We reduced the n-dimensional space formed by a given set of SNPs to a single dimension to analyze n-way interactions. We calculated score-based statistics using maximum-likelihood estimates to classify multifactor cells into two different groups (either high risk or low risk). This was performed for all possible combinations of SNPs, and the combination with the lowest misclassification error was selected. Moreover, we tested all possible 2-locus to 4-locus interactions using 10-fold cross-validation (CV) in an exhaustive search, which considers all possible SNP combinations. In addition, we performed logistic regression models to confirm the results from GMDR analyses. Power analysis for case-control samples was carried out by G*Power program (alpha has been set at 0.05).

Author Contributions

Conceived and designed the experiments: ZL WL. Performed the experiments: ZX KG QW. Analyzed the data: GW CY. Contributed reagents/materials/analysis tools: HW XW. Wrote the paper: ZX ZL.

References

1. Kessler RC, McGonagle KA, Zhao S, Nelson CS, Hughes M, et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.

2. Duffy A, Geof P, Roberton C, Alda M (2000) The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 61: 630–637.

3. Levinson DF (2006) The genetics of depression: a review. Biol Psychiatry 60: 84–92.

4. Karage F, Perret G, Bondolli G, Schwald M, Bertschy G, et al. (2002) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 145–148.

5. Schule C, Zill P, Baghai TC, Eser D, Zwanzger P, et al. (2006) Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31: 1019–25.

6. Lezoualch F, Engert S, Berning B, Böhl C (2000) Corticotropin-releasing hormone mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14: 147–159.

7. Hauger RL, Rashbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM (2009) Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci 1179: 120–143.

8. Bayati N, Hermann H, Lutz B, Böhl C (2005) CRH-mediated induction of intracellular signaling pathways and BDNF expression is inhibited by the activation of the endocannabinoid system. Endocrinology 146: 1205–1213.

9. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB (1996) Corticotrophin-releasing factor receptors from molecular biology to drug design. Trends Pharmacol Sci 17: 166–172.

10. Van Pett K, Viau V, Bittenbouer JC, Chan RK, Li HY, et al. (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neuro 428: 191–212.

11. Galer D, Unscier K (2000) Brain-derived neurotrophic factor and trkB are essential for cAMP-mediated induction of the serotonergic neuronal phenotype. J Neurosci Res 61: 295–301.

12. Ghosh A, Carnahan J, Greenberg ME (1994) Requirement for BDNF in activity dependent survival of cortical neurons. Science 263: 1618–1623.

13. Lacivinio J, O’kivsin F, Frazar Y, Merriman B, Thakur S, et al. (2004) Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 9: 1073–1082.

14. Liu ZG, Zhu F, Wang GH, Xiao ZM, Wang HL, et al. (2006) Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 404: 358–362.
15. Liu ZC, Zhu F, Wang GH, Xiao ZM, Tang JH, et al. (2007) Association study of corticotrophin releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414: 155–158.

16. Ressler KJ, Bradley B, Mercer KB, Deveau TC, Smith AK, et al. (2010) Polymorphisms in CRHR1 and the serotonin transporter loci: gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 153B: 812–824.

17. Egan MF, Koimia JH, Goldberg TE, Kolachana BS, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257–269.

18. Saarelaine T, Hendolin P, Lasca G, Koponen E, Sairanen M, et al. (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant induced behavioral effects. J Neurosci 23: 349–357.

19. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116–1127.

20. Carlborg O, Haley CS (2004) Epistasis: too often neglected in complex trait studies. Nature, 5: 618–625.

21. Holmans P, Zubenko GS, Crowe RR, DPaulo JJ, Scheffner WA, et al. (2004) Genomewide significant linkage to recurrent, early-onset major depressive disorder on chromosome 15q. Am J Hum Genet 74: 1154–1167.

22. Zubenko GS, Zubenko WN, Spiker DG, Giles DE, Kaplan BB (2001) Malignancy of recurrent early-onset major depression: a family study. Am J Med Genet 105: 690–699.

23. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lin JF, et al. (2006) The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with geriatric depression. Neurobiol Aging 27: 1834–1837.

24. Jing X, Xu K, Heberman J, Tian F, Marko AJ, et al. (2005) BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30: 1353–1361.

25. Oswald P, Del-Favero J, Massai I, Sossey D, Claus S, et al. (2005) No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies. Eur Neuropsychopharmacol 15: 491–495.

26. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, et al. (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58: 307–314.

27. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ (2003) Association study of a brain derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B: 19–22.

28. Botto LD, Khoury MJ (2001) Commentary: facing the challenge of gene environment interaction: the two-by-four table and beyond. Am J Epidemiol 153: 1016–1020.

29. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, et al. (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59: 812–815.

30. American-Psychiatric-Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th ed). American Psychiatric Association: Washington, DC.

31. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology Revised. Washington DC, US Department of Health, Education, and Welfare, pp 218–221.

32. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278–296.

33. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.

34. Raymond M, Rousset F (1995) GENEPOP (version 1.2). Population genetics software for exact tests and ecumenicism. J Hered 86: 248–249.

35. Schneider S, Roessli D, Excoffier L (2000) Arlequin: a software for population genetics data analysis, Ver. 2.000 University of Geneva.

36. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, et al. (2007) A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 80: 1125–1137.